GlassScriptPhysician profile
Amy V Gorczynski
NPI 1225022437
$10,398.18
in general payments reported to CMS, 2019-2025
48 companies · $862 in 2025
The $862 reported for 2025 was more than what 83% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,395 · 2020: $1,815 · 2021: $2,525 · 2022: $1,530 · 2023: $1,652 · 2024: $621 · 2025: $862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,134.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,375.75 | 2020-2024 | |
| Allergan, INC. | $877.22 | 2019-2020 | |
| Pfizer INC. | $851.48 | 2019-2025 | |
| Lilly USA, LLC | $768.46 | 2019-2025 | Mounjaro, Zepbound, Emgality |
| Astrazeneca Pharmaceuticals LP | $532.87 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Novo Nordisk INC | $411.63 | 2020-2025 | Ozempic, Wegovy, Rybelsus |
| Bausch Health US, LLC | $409.85 | 2020-2023 | Aplenzin, Wellbutrin |
| Amgen INC. | $404.74 | 2019-2025 | Otezla, Repatha, Repatha |
| Daiichi Sankyo INC. | $379.97 | 2020-2025 | Injectafer |
| Glaxosmithkline, LLC. | $359.01 | 2019-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Teva Pharmaceuticals USA, INC. | $348.73 | 2019-2023 | Austedo Xr |
| Astellas Pharma US INC | $306.25 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $294.77 | 2019-2024 | Xifaxan, Trulance |
| Novartis Pharmaceuticals Corporation | $244.42 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $227.72 | 2019-2024 | Gardasil, Gardasil 9, Capvaxive |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Gorczynski listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.